News
QIAGEN und SOPHiA GENETICS gehen Partnerschaft ein und bündeln Next-Generation-Sequencing-Kompetenzen
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) startet das „QIAseq Platform Partnership“-Programm und gibt die erste Partnerschaft mit SOPHiA GENETICS™ (Nasdaq: SOPH) bekannt, einem
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
ICON plc to Present at Upcoming Investor Conferences
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2023 Citi
Acadia Healthcare Reports Fourth Quarter 2022 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2022.
Fourth Quarter Highlights
-
Revenue totaled $675.3
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Convatec Group PLC: Director/PDMR Shareholding
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Chemed Reports Fourth-Quarter 2022 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2022. Novocure is a global oncology company working to extend survival in some of
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors.
“We are honored to welcome Dr. Ocean to our board of directors,” said
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
ICON Reports Fourth Quarter and Full Year 2022 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the fourth quarter and year ended December 31, 2022.
Premier Inc. Acquires 100 Top Hospitals® Program
Premier Inc. (NASDAQ: PINC) acquired the 100 Top Hospitals® program from Merative (formerly IBM Watson Health). The program will be integrated within PINC AI™, Premier’s technology and services
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2022 and provided guidance for 2023. For the quarter, revenue was $1.10
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
LivaNova Reports Fourth-Quarter and Full-Year 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Almirall’s Full-Year 2022 Results
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2022 financial results today.
Financial highlights (€ rounded million)
Chemed Corporation Declares Quarterly Dividend of 38 Cents
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company’s capital stock, payable on March 17, 2023, to